Efficacy and Safety of Alogliptin Plus Metformin Compared to Glipizide Plus Metformin in Patients With Type 2 Diabetes Mellitus
Completed
Takeda
Phase 3
2009-03-01
The purpose of this study is to determine the safety and effectiveness of adding alogliptin,
once daily (QD), compared to glipizide with metformin in diabetic patients.
Roflumilast Plus Alogliptin Proof-of-Mechanism Study in Type2 Diabetes
Completed
AstraZeneca
Phase 1
2012-07-01
The purpose of this study is to assess the effect of roflumilast plus alogliptin on
glucagon-like peptide-1 (GLP-1) and glucose levels in patients with type 2 diabetes.
Roflumilast Plus Alogliptin Proof-of-Mechanism Study in Type2 Diabetes
Completed
Takeda
Phase 1
2012-07-01
The purpose of this study is to assess the effect of roflumilast plus alogliptin on
glucagon-like peptide-1 (GLP-1) and glucose levels in patients with type 2 diabetes.
Alogliptin Tablets Special Drug Use Surveillance "Type 2 Diabetes Mellitus: Monotherapy/Combination Therapy With α-GI"
Completed
Takeda
2010-07-08
The purpose of this study is to determine the safety and efficacy of long-term treatment with
alogliptin (Nesina) in patients with type 2 diabetes mellitus who responded inadequately to
diet therapy and exercise therapy alone, or a combination of diet therapy, exercise therapy,
and α-glucosidase inhibitor.
In addition, examining the safety and efficacy of alogliptin in patients with renal
impairment, information on the appropriate dosage of alogliptin according to the severity of
impaired renal function should be collected.
Alogliptin Tablets Special Drug Use Surveillance "Type 2 Diabetes Mellitus: Combination Therapy With Thiazolidinediones"
Completed
Takeda
2011-03-01
The purpose of this study is to determine the safety and efficacy of long-term combination
therapy with alogliptin (Nesina) and thiazolidinediones in patients with type 2 diabetes
mellitus who failed to respond adequately to treatment with thiazolidinediones in addition to
diet therapy and exercise therapy.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models.
By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
